Hyloris Pharmaceuticals SA

ENXTBR:HYL Stock Report

Market Cap: €336.0m

Hyloris Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Hyloris Pharmaceuticals's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 48.3% per year.

Key information

-18.4%

Earnings growth rate

3.5%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate48.3%
Return on equity-40.6%
Net Margin-560.1%
Next Earnings Update30 Apr 2024

Recent past performance updates

Recent updates

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28
Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08
Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Revenue & Expenses Breakdown
Beta

How Hyloris Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTBR:HYL Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233-16615
30 Sep 232-15514
30 Jun 233-12512
31 Mar 233-12411
31 Dec 222-12410
30 Sep 223-1039
30 Jun 223-838
31 Mar 223-1037
31 Dec 213-1235
30 Sep 212-1224
30 Jun 211-1213
31 Mar 211-1023
31 Dec 200-723
30 Sep 200-832
30 Jun 200-832
31 Mar 200-612
31 Dec 190-511
31 Dec 180-615
31 Dec 170-422

Quality Earnings: HYL is currently unprofitable.

Growing Profit Margin: HYL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HYL is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.

Accelerating Growth: Unable to compare HYL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HYL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).


Return on Equity

High ROE: HYL has a negative Return on Equity (-40.6%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.